Lerato Mohapi to Viral Load
This is a "connection" page, showing publications Lerato Mohapi has written about Viral Load.
Connection Strength
0,472
-
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019 09; 6(9):e588-e600.
Score: 0,124
-
CD4 counts and viral loads of newly diagnosed HIV-infected individuals: implications for treatment as prevention. PLoS One. 2014; 9(3):e90754.
Score: 0,085
-
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012 Aug; 13(7):406-15.
Score: 0,074
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
Score: 0,038
-
Factors Associated With and Characteristic of HIV/Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants. J Acquir Immune Defic Syndr. 2021 05 01; 87(1):720-729.
Score: 0,035
-
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 01; 4(1):e13-e20.
Score: 0,026
-
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015 Jul; 15(7):793-802.
Score: 0,023
-
The impact of highly active antiretroviral therapy on activities of daily living in HIV-infected adults in South Africa. AIDS Behav. 2011 May; 15(4):823-31.
Score: 0,017
-
Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS. 2010 Nov 13; 24(17):2687-96.
Score: 0,017
-
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
Score: 0,017
-
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15; 201(6):803-13.
Score: 0,016